Over 70 health care experts from Oregon are petitioning the Food & Drug Administration (FDA) to make Naloxone nasal spray available without a prescription. Naloxone is a fast acting drug that can prevent the death of people who are experiencing an opioid drug overdose.
Among the study’s top findings was the revelation that pain-related disability identifies a substantial portion of the chronic pain population experiencing progressive deterioration in mental and physical health outcomes along with substantially higher health care usage. Together, the High Impact Chronic Pain (HICP) population constitutes some 4.8 percent of the U.S. adult population. About 83 percent of people with HICP were unable to work for a living, and one-third had difficulty with self-care activities such as washing themselves and getting dressed.